<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672252</url>
  </required_header>
  <id_info>
    <org_study_id>19-01293</org_study_id>
    <nct_id>NCT04672252</nct_id>
  </id_info>
  <brief_title>The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy</brief_title>
  <official_title>The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy; A Double-Blind, Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effects of administering CBD to control post-operative&#xD;
      pain in patients undergoing shoulder arthroscopy. Secondly, the purpose will be to evaluate&#xD;
      the effectiveness of CBD in comparison with opioid therapy for post-operative pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on Pain Visual Analog Scale (VAS)</measure>
    <time_frame>14 days</time_frame>
    <description>Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; 0 = no pain, 10 = worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nauseau on VAS scale</measure>
    <time_frame>14 days</time_frame>
    <description>Any nausea experienced by the patients will be recorded by use of a VAS (0 = no nausea, 10 = worst nausea imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CBD consumption</measure>
    <time_frame>Day 1, 7, 14</time_frame>
    <description>patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Day 1, 7, 14</time_frame>
    <description>patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>Day 1, 7, 14</time_frame>
    <description>Patients will record their satisfaction with their management, on a 0-10 scale, 24 hours, 2 days and 7 days, and 14 days after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBD Oral Disintegrating Tablet (ODT)</intervention_name>
    <description>Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo ODT</intervention_name>
    <description>Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.&#xD;
The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients undergoing an arthroscopic shoulder procedure (rotator cuff repair,&#xD;
             decompression, labrum repair)&#xD;
&#xD;
          -  Patients ages 18-75, inclusive&#xD;
&#xD;
          -  Female patients must be currently practicing effective forms of two types of birth&#xD;
             control, which are defined as those, alone or in combination, that result in a low&#xD;
             failure rate (less than 1% per year) when used consistently and correctly&#xD;
&#xD;
          -  Male patients must be using an effective form of contraception&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects,&#xD;
             dementia, etc.)&#xD;
&#xD;
          -  Younger than 18 years of age&#xD;
&#xD;
          -  Older than 75 years of age&#xD;
&#xD;
          -  Any patient considered a vulnerable subject: pregnant women or fetuses, children,&#xD;
             cognitively impaired adults, prisoners&#xD;
&#xD;
          -  History of cannabis abuse or dependence&#xD;
&#xD;
          -  History of coagulation abnormalities and thromboembolic disease or current abnormal&#xD;
             coagulation test values&#xD;
&#xD;
          -  History of stroke or acute coronary syndromes within 3 months before surgery&#xD;
&#xD;
          -  Abnormal coagulation profile&#xD;
&#xD;
          -  Renal failure (serum creatinine &gt; 250 Î¼mol/L [2.83 mg/dL]) or liver cirrhosis&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to Percocet&#xD;
&#xD;
          -  Patients that have been on pre-operative opioid management for any reason&#xD;
&#xD;
          -  Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder&#xD;
&#xD;
          -  Patients diagnosed with major depression, psychosis, or substance abuse disorder&#xD;
&#xD;
          -  Patients with current or a history of suicidal ideation&#xD;
&#xD;
          -  Breastfeeding females&#xD;
&#xD;
          -  Patients with clinically significant illness, including cardiovascular disorders&#xD;
&#xD;
          -  Clinically significant lab abnormalities&#xD;
&#xD;
          -  Abnormal LFTs&#xD;
&#xD;
          -  Patients with major neurological disorders, such as dementia, Parkinson's disease,&#xD;
             cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures&#xD;
&#xD;
          -  Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).&#xD;
&#xD;
          -  Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below)&#xD;
             concomitantly&#xD;
&#xD;
          -  Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly&#xD;
&#xD;
          -  Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and&#xD;
             CYP2C19 (listed below) concomitantly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Alaia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Alaia, MD</last_name>
    <phone>(646)-501-7223</phone>
    <email>michael.alaia@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kinjal Vasavada</last_name>
    <email>kinjal.vasavada@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eoghan Hurley, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to the PI. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

